Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Q3 FY26 Earnings Presentation
21 slides from Botanix Pharmaceuticals's earnings presentation, Apr 29, 2026
Slide 1: Investor Update Q3 FY26
For personal use only Investor Update Q3 29 APRIL 2026 FY26 www.botanixpharma.com
Slide 2: Important Notices & Disclaimer
Important Notices & Disclaimer 1. Summary information 6. Forward-looking statements and forecasts The following notice and disclaimer applies to this investor presentation (“Presentation”) and you are therefore advised to This Presentation contains certain “forward-looking statements” and comments a
Slide 3: Corporate Overview: Growing dermatology pharmaceutical company
CORPORATE OVERVIEW Growing dermatology pharmaceutical company For personal use only with high physician satisfaction for Sofdra® Dermatology Focused Innovative Platform Capital Position Positioned for Growth Sofdra is the first and only Fulfilment platform Pro forma cash of $50.8m 50 highly producti
Slide 4: Botanix is led by an experienced group of dermatology executives
Botanix is led by an experienced group of dermatology executives VINCE IPPOLITO HOWIE MCKIBBON For personal use only Executive Chairman Chief Executive Officer >30 successful CAREY HERBERT CHRIS LESOVITZ LEISHA MARTIN dermatology Chief Legal & Compliance Officer Chief Financial Officer, U.S. VP, Qua
Slide 5: Botanix key accomplishments in the trailing months
Botanix key accomplishments in the trailing 12 months Cumulative Gross Revenue Cumulative Net Revenue Cumulative Total Prescriptions $118.7 $27.4 86.0k use only 140 30 100 million million 90 shipped 120 25 80 100 70 20 Thousands 80 60 For personalMillions Millions 15 50 60 40 10 40 30 5 20 20 10 0 0
Slide 6: Record TRx in March, confident in continuing sales momentum
With a record TRx in March, Botanix is confident in continuing sales momentum for Sofdra® For personal use only Highlights New TRx Record Capital Raise Pro Forma Cash API Renegotiation Alt API Supplier Selected 10,653 $45m $50.8m ~US$15m 25%–40% in March Completed in April & Cash Equivalents Payment
Slide 7: Growth in Volume of Total Prescriptions Shipped
Growth in Volume of Total Prescriptions Shipped Sofdra® TRx shipments grew to For personal use only 26.7k 25.3k 26,684 in Q3 FY26 20.4k v March set an all-time high for Sofdra with TRx shipments of 10,653 13.6k v Continued growth through seasonal slowdown v Growth is accelerating Q4 FY2025 Q1 FY2026
Slide 8: Sofdra Net Revenue
Sofdra® Net Revenue Net revenue in line with expectations due to For personal use only $9.1m annual deductible reset v TRxs increased while gross-to-net $7.1m $6.9m was temporarily impacted v Annual deductible reset occurs in January, when US health insurance $4.3m resets, requiring patients to pay
Slide 9: GTN Yield
GTN Yield Annual deductible reset 24% 23% temporarily depressed For personal use only 21% gross-to-net yield 18% 15% v GTN showed improvement throughout the quarter, growing from 16% – 19% for Q3 FY26 v Gross-to-net expected to resume its upward trajectory in Q4 Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY20
Slide 10: Q3 FY26: Strong capital and inventory positions support growth
Q3 FY26: Strong capital and inventory positions support growth For personal use only $50.8m ~$34.5m $(13.6m) PRO FORMA Q3 CASH1 INVENTORY BALANCE OPERATING CASH OUTFLOW without $9.7m API purchase Cash and cash equivalents of $22.1m2 Botanix has an adequate supply Operating net cash outflows Addition
Slide 11: Net cash outflow decreased 21%, absent API purchase
Net cash outflow Cash flows from operating activities 30 Jun 25 30 Sep 25 31 Dec 25 31 Mar 26 decreased 21%, Receipts from Royalties Receipts from product sales, net of fees 195 3,836 504 8,271 435 11,890 216 11,252 absent API purchase Payments for gross to net deductions from product sales Payments
Slide 12: Potential impact of US pharmaceutical tariffs announced April
Potential impact of US pharmaceutical tariffs announced 2 April Botanix is still evolving our response to tariffs expected to take effect on 29 September 2026 For personal use only Expected impact of announced tariffs: Botanix is exploring options to ~US$10 tariff per bottle reduce or delay tariff i
Slide 13: Renegotiated API supply agreement defers ~US$15m payments
Renegotiated API supply agreement defers ~US$15m payments over future years to smooth cash flow For personal use only Original API Purchase Schedule One purchase by December of each year CY2026 CY2027 CY2028 CY2029 2030 •• • • • • APRIL JANUARY MARCH DECEMBER Three purchases spread over two years Re
Slide 14: Term sheet agreement with second API supplier
Botanix reaches term sheet agreement with second API supplier on 16 April 2026 For personal use only Potential 25% – 40% reduction in cost of goods sold and increased gross profit The Company has agreed to terms with PPL Pharma Solutions v Technical transfer to commence immediately Riverview LLC (“P
Slide 15: Strong pro forma balance sheet improves working capital
Strong pro forma balance sheet improves working capital to drive the company’s future growth For personal use only Impact of Capital Raise Q3 ending cash $22.1 $23.8m $4.9m ~$50.8m Includes Tranche 1 Tranche 2 SPP Pro Forma Q3 Cash and API payment www.botanixpharma.com 15
Slide 16: Catalysts to drive Botanix performance
Catalysts to drive Long IP runway to 2040 Botanix performance Expand Sofdra elevates Botanix value proposition for licensing to other mergers & acquisitions For personal use only regions for Alternate API increased revenue supplier to decrease Add new products COGS 25% – 40% to platform to accelerat
Slide 17: Committed to delivering dermatology solutions in underserved markets
Botanix is committed to delivering dermatology solutions to patients in large, underserved markets with high unmet need For personal use only Sofdra (sofpironium) Botanix acquired worldwide exclusive rights to sofpironium; patent protection through mid-2040 topical gel, 12.45% FDA-approved treatment
Slide 18: Sofdra is the first and only new chemical entity for primary axillary hyperhidrosis
Sofdra® is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option Hyperhidrosis is a medical condition characterised by excessive FDA-Approved Indication2 For personal use only sweating beyond what is needed to maintain normal body
Slide 19: Common Skin Diseases
Common Skin Diseases Botanix is actively Indication # of patients evaluating expansion Acne ~50m For personal use only opportunities within Atopic dermatitis ~31m dermatology Hyperhidrosis* ~16.1m v Dermatology is a large and expanding market with ~10% CAGR Rosacea ~15m – $8B in 2024 / ~$14.5B by 20
Slide 20: Validated Botanix Fulfilment Platform primed for additional products
Validated Botanix Fulfilment Platform is primed for acquisition of additional products at a low incremental cost For personal use only ü Seamless fulfillment ü Increase reimbursed Rx PRESCRIBER PATIENT PHARMACY WHOLESALER CO-PAY Consigned DISCOUNT ü High fill and refill rates I’ve never used a speci
Slide 21: Three key pillars drive Botanix's near- and long-term value
Three key pillars drive Botanix’s near- and long-term value Strong Opportunity Differentiated Solid Foundation for For personal use only for Sofdra® Fulfilment Platform Growth & Profitability v Large underserved market of v Improves gross to net yield v Manufacturing efficiencies 10 million patients
Botanix Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix